Linzolid is indicated for the treatment of:
Linzolid is ineffective against Gram-negative pathogens. Its safety and efficacy beyond 28 days of continuous use have not been established in clinical trials.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Linezolid is a synthetic antimicrobial agent classified as an oxazolidinone. It exhibits potent activity primarily against aerobic Gram-positive bacteria, some Gram-positive anaerobes, and selected Gram-negative species. Its mechanism involves selective inhibition of bacterial protein synthesis by binding to the 23S ribosomal RNA on the 50S ribosomal subunit. This action prevents the assembly of a functional 70S initiation complex, which is essential for bacterial translation.
Bacteriostatic: Against Enterococci and Staphylococci
Bactericidal: Against most strains of Streptococci
Linzolid is available as oral tablets and intravenous infusion. It can be taken with or without food. IV infusion must be administered over 30–120 minutes.
Infection | Pediatric (0–11 yrs) | Adults & Adolescents (12+ yrs) | Duration |
---|---|---|---|
Nosocomial pneumonia | 10 mg/kg every 8 hr (oral/IV) | 600 mg every 12 hr (oral/IV) | 10–14 days |
Community-acquired pneumonia, Complicated SSTI | 10 mg/kg every 8 hr (oral/IV) | 600 mg every 12 hr (oral/IV) | 14–28 days |
Uncomplicated SSTI | <5 yrs: 10 mg/kg every 8 hr (oral) 5–11 yrs: 10 mg/kg every 12 hr (oral) | Adults: 400 mg every 12 hr (oral) Adolescents: 600 mg every 12 hr (oral) | 10–14 days |
Neonates (<7 days, <34 weeks GA): Begin with 10 mg/kg every 12 hours. If clinical response is inadequate, 10 mg/kg every 8 hours may be considered. By day 7, switch to 10 mg/kg every 8 hours.
No dose adjustment is needed when switching between IV and oral forms.
IV Administration: Inspect the infusion visually for particulates. A yellow tint may develop without affecting potency. Avoid series connections or adding substances to the solution. Discard any unused solution after a single use.
Hepatic impairment: No adjustment needed in mild-to-moderate cases. Not studied in severe hepatic dysfunction.
Pediatric CNS infections: Not recommended for empirical treatment.
With medications: Linezolid is a reversible non-selective MAO inhibitor. It may enhance the pressor response to sympathomimetics and pose a risk of serotonin syndrome when co-administered with SSRIs, TCAs, triptans, buspirone, or meperidine.
With food: Patients should avoid tyramine-rich foods (e.g., aged cheese, fermented meats).
Pregnancy: Limited data suggest no major fetal risks. Use only if needed.
Breastfeeding: Linezolid is present in breast milk. Monitor infants for gastrointestinal symptoms.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.